Judi van Diessen

890 citations

14 papers · 460 indexed · h-index 7

Otorhinolaryngology top 5%
- Head and Neck Cancer Studies 2
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Diagnosis and Treatment 7
- Lung Cancer Treatments and Mutations 5
- Radiation Therapy and Dosimetry 2
Radiology, Nuclear Medicine and Imaging top 10%
- Radiomics and Machine Learning in Medical Imaging 5
- Medical Imaging Techniques and Applications 4
Radiation top 10%
- Advanced Radiotherapy Techniques 2
Nephrology
Oncology
- Neutropenia and Cancer Infections 1

Co-authors: J. Belderbos Erik van Werkhoven Jan‐Jakob Sonke Mark M. Schubert Judith E. Raber‐Durlacher Ludi E. Smeele Margot Tesselaar Liset Lansaat
Cited by: Otorhinolaryngology Pulmonary and Respiratory Medicine Radiology, Nuclear Medicine and Imaging
Journals: Clinical Cancer Research (1 paper)International Journal of Radiation Oncology*Biology*Physics (2 papers)Radiotherapy and Oncology (6 papers)
Partner nations: Netherlands Belgium Denmark

In The Last Decade

Judi van Diessen

12 papers receiving 454 citations

Peers

Countries citing papers authored by Judi van Diessen

Since Specialization

Citations

This map shows the geographic impact of Judi van Diessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judi van Diessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judi van Diessen more than expected).

Fields of papers citing papers by Judi van Diessen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judi van Diessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judi van Diessen. The network helps show where Judi van Diessen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Judi van Diessen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Judi van Diessen Line = papers co-authored together Judi van Diessen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial International Journal of Radiation OncologyBiologyPhysics ·Saskia A. Cooke,J. Belderbos,Barbara Stam,Bart Reymen,Maarten Lambrecht,Gitte Fredberg Persson,Corinne Faivre‐Finn,Edith Dieleman,Judi van Diessen,Dirk De Ruysscher,Jan‐Jakob Sonke	2025	0
2	Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC International Journal of Radiation OncologyBiologyPhysics ·Susie Cooke,Dirk De Ruysscher,Bart Reymen,Maarten Lambrecht,Gitte Fredberg Persson,Corinne Faivre‐Finn,Edith Dieleman,Judi van Diessen,Karolina Sikorska,Ferry Lalezari,Jan‐Jakob Sonke,J. Belderbos	2021	0
3	OA02.05 Local, Regional and Pulmonary Failures in the Randomised PET-Boost Trial for NSCLC Patients Journal of Thoracic Oncology ·Susie Cooke,Dirk De Ruysscher,Bart Reymen,Maarten Lambrecht,Gitte Fredberg Persson,Corinne Faivre‐Finn,Edith Dieleman,Judi van Diessen,Karolina Sikorska,Ferry Lalezari,Jan‐Jakob Sonke,J. Belderbos	2021	3
4	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer Clinical Cancer Research ·Rosemarie de Haan,Michel M. van den Heuvel,Judi van Diessen,Heike Peulen,Erik van Werkhoven,Adrianus J. de Langen,Ferry Lalezari,Dick Pluim,Manon Verwijs-Janssen,Conchita Vens,Jan H.M. Schellens,Neeltje Steeghs,Marcel Verheij,Baukelien van Triest	2020	39
5	OC-0609: The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC Radiotherapy and Oncology ·Samuel Cooke,Dirk De Ruysscher,Bart Reymen,Maarten Lambrecht,Gitte Fredberg Persson,Corinne Faivre‐Finn,Edith Dieleman,Rolf Lewensohn,Judi van Diessen,Karolina Sikorska,Ferry Lalezari,J.J. Sonke,J. Belderbos	2020	4
6	The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial) Radiotherapy and Oncology ·Judi van Diessen,Dirk De Ruysscher,Jan‐Jakob Sonke,E. Damen,Karolina Sikorska,Bart Reymen,Wouter van Elmpt,Gunnar Westman,Gitte Fredberg Persson,Edith Dieleman,Hedvig Björkestrand,Corinne Faivre‐Finn,J. Belderbos	2018	53
7	A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II–III NSCLC Radiotherapy and Oncology ·M. La Fontaine,Wouter V. Vogel,Judi van Diessen,Wouter van Elmpt,Bart Reymen,Gitte Fredberg Persson,Gunnar Westman,Dirk De Ruysscher,J. Belderbos,Jan‐Jakob Sonke	2018	4
8	Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy Radiotherapy and Oncology ·Barbara Stam,Erik van der Bijl,Judi van Diessen,Maddalena Rossi,A. Tijhuis,J. Belderbos,E. Damen,Jan‐Jakob Sonke	2017	38
9	Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols Supportive Care in Cancer ·Judith A. E. M. Zecha,Judith E. Raber‐Durlacher,Raj Nair,Joel B. Epstein,Sharon Elad,Michael R. Hamblin,Andrei Barasch,César A. Migliorati,Dan M.J. Milstein,Marie-Thérèse Genot,Liset Lansaat,Ron van der Brink,Josep Arnabat‐Domínguez,Lisette van der Molen,Irene Jacobi,Judi van Diessen,Jan de Lange,Ludi E. Smeele,Mark M. Schubert,René‐Jean Bensadoun	2016	170
10	Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab Radiotherapy and Oncology ·Iris Walraven,Michel M. van den Heuvel,Judi van Diessen,Eva Schaake,Wilma Uyterlinde,Joachim G.J.V. Aerts,Frederieke Koppe,Henk Codrington,Peter W.A. Kunst,Edith Dieleman,Paul van de Vaart,Marcel Verheij,J. Belderbos	2016	54
11	Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas Cancers ·J.F. Van den Hoek,Karen Bloemendal,Lilly-Ann van der Velden,Judi van Diessen,Erik van Werkhoven,W. Martin C. Klop,Margot Tesselaar	2016	61
12	OC-0204: The first toxicity results of the PET-boost trial (NCT01024829) Radiotherapy and Oncology ·Judi van Diessen,D. De Russcher,Jan‐Jakob Sonke,E. Damen,Karolina Sikorska,Gunnar Westman,Bart Reymen,J. Belderbos	2015	2
13	VERY HIGH RADIATION DOSE ESCALATION IN NSCLC DOES NOT LEAD TO UNEXPECTED TOXICITY: A PLANNED TOXICITY ANALYSIS OF THE PET-BOOST STUDY (NCT01024829) Judi van Diessen,J. Belderbos,J.J. Sonke,Harm van Tinteren,Wouter V. Vogel,E. Damen,Bart Reymen,Wouter van Elmpt,Dirk De Ruysscher	2013	1
14	5-Oxoproline as a cause of high anion gap metabolic acidosis: an uncommon cause with common risk factors. PubMed ·W. Kortmann,Michiel A. van Agtmael,Judi van Diessen,B.L. Kanen,C.A.J.M. Jakobs,Prabath W.B. Nanayakkara	2008	31

About Judi van Diessen

Judi van Diessen is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 14 papers that have together received 460 indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (7 papers), Radiomics and Machine Learning in Medical Imaging (5 papers), Lung Cancer Treatments and Mutations (5 papers), Medical Imaging Techniques and Applications (4 papers), Head and Neck Cancer Studies (2 papers), Radiation Therapy and Dosimetry (2 papers), Advanced Radiotherapy Techniques (2 papers) and Neutropenia and Cancer Infections (1 paper). The work is most often cited by research in Otorhinolaryngology (82 citations), Pulmonary and Respiratory Medicine (287 citations) and Radiology, Nuclear Medicine and Imaging (201 citations). Judi van Diessen has collaborated with scholars based in Netherlands, Belgium and Denmark. Frequent co-authors include J. Belderbos, Erik van Werkhoven, Jan‐Jakob Sonke, Mark M. Schubert, Judith E. Raber‐Durlacher, Ludi E. Smeele, Margot Tesselaar, Liset Lansaat, W. Martin C. Klop and Jan de Lange. Their work appears in journals such as Clinical Cancer Research, International Journal of Radiation Oncology*Biology*Physics and Radiotherapy and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact